About Chiasma (NASDAQ:CHMA)
Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:CHMA
- CUSIP: N/A
- Web: www.chiasmapharma.com
- Market Cap: $60.9 million
- Outstanding Shares: 24,359,000
- 50 Day Moving Avg: $2.52
- 200 Day Moving Avg: $2.52
- 52 Week Range: $1.55 - $2.95
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.75
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $3.04 per share
- Price / Book: 0.82
- EBITDA: ($29,420,000.00)
- Return on Equity: -35.96%
- Return on Assets: -31.97%
- Current Ratio: 10.40%
- Quick Ratio: 10.40%
- Average Volume: 78,720 shs.
- Beta: 1.38
- Short Ratio: 18.76
Frequently Asked Questions for Chiasma (NASDAQ:CHMA)
What is Chiasma's stock symbol?
Chiasma trades on the NASDAQ under the ticker symbol "CHMA."
How were Chiasma's earnings last quarter?
Chiasma, Inc. (NASDAQ:CHMA) released its quarterly earnings data on Friday, May, 5th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.06. View Chiasma's Earnings History.
When will Chiasma make its next earnings announcement?
Are investors shorting Chiasma?
Chiasma saw a decrease in short interest during the month of September. As of September 29th, there was short interest totalling 442,548 shares, a decrease of 35.1% from the September 15th total of 681,631 shares. Based on an average trading volume of 85,511 shares, the days-to-cover ratio is currently 5.2 days. Approximately 3.7% of the shares of the stock are short sold.
Who are some of Chiasma's key competitors?
Some companies that are related to Chiasma include KalVista Pharmaceuticals (KALV), Alimera Sciences (ALIM), VIVUS (VVUS), Opiant Pharmaceuticals (OPNT), Cardiome Pharma Corporation (CRME), Cesca Therapeutics (KOOL), Tokai Pharmaceuticals (NVUS), Ocera Therapeutics (OCRX), Onconova Therapeutics (ONTX), Catalyst Biosciences (CBIO), Sonoma Pharmaceuticals (SNOA), Argos Therapeutics (ARGS), Auxilium Pharmaceuticals (AUXL), Baxalta (BXLT), Horizon Therapeutics (HPTX), Ocera Therapeutics (TZYM), Transition Therapeutics (TTHI) and Vitae Pharmaceuticals (VTAE).
Who are Chiasma's key executives?
Chiasma's management team includes the folowing people:
- David M. Stack, Independent Chairman of the Board
- Mark J. Fitzpatrick, President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
- Drew Enamait, Principal Accounting Officer, Vice President - Finance & Administration, Corporate Controller
- Roni Mamluk Ph.D., Director
- Todd Foley, Independent Director
- Bard J. Geesaman M.D. Ph.D., Independent Director
- Scott Minick, Independent Director
- John A. Scarlett M.D., Independent Director
When did Chiasma IPO?
(CHMA) raised $76 million in an IPO on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.
How do I buy Chiasma stock?
Shares of Chiasma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chiasma's stock price today?
MarketBeat Community Rating for Chiasma (NASDAQ CHMA)MarketBeat's community ratings are surveys of what our community members think about Chiasma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Chiasma stock can currently be purchased for approximately $2.50.
Consensus Ratings for Chiasma (NASDAQ:CHMA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating|
|Consensus Rating:||Sell (Score: 1.00)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Chiasma (NASDAQ:CHMA)
Analysts' Ratings History for Chiasma (NASDAQ:CHMA)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|1/17/2017||Barclays PLC||Downgrade||Equal Weight -> Underweight||N/A|
|5/13/2016||Cowen and Company||Reiterated Rating||Hold||N/A|
|4/18/2016||Oppenheimer Holdings, Inc.||Reiterated Rating||Outperform||$43.00 -> $9.00||N/A|
|4/18/2016||William Blair||Downgrade||Outperform -> Market Perform||N/A|
Earnings History for Chiasma (NASDAQ:CHMA)Earnings History by Quarter for Chiasma (NASDAQ CHMA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Chiasma (NASDAQ:CHMA)
Current Year EPS Consensus Estimate: $-0.96 EPS
Next Year EPS Consensus Estimate: $-1.43 EPS
Dividend History for Chiasma (NASDAQ:CHMA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Chiasma (NASDAQ:CHMA)
Insider Ownership Percentage: 3.80%Insider Trades by Quarter for Chiasma (NASDAQ:CHMA)
Institutional Ownership Percentage: 50.40%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/21/2017||Scott Minick||Director||Buy||25,000||$2.37||$59,250.00|| |
|9/20/2017||Scott Minick||Director||Buy||15,000||$2.38||$35,700.00|| |
|7/21/2015||Health Ventures Lp 7-Med||Major Shareholder||Buy||93,750||$16.00||$1,500,000.00|| |
Headline Trends for Chiasma (NASDAQ:CHMA)
Latest Headlines for Chiasma (NASDAQ:CHMA)
Loading headlines, please wait.
Chiasma (CHMA) Chart for Sunday, October, 22, 2017